SCHEDULE: Millennium Entities Report 8.2% Stake in Reviva Pharma

Integrated Core Strategies, Millennium Management, and Israel A. Englander have jointly reported beneficial ownership of 8.2% of Reviva Pharmaceuticals Holdings, Inc. common stock.

Summary

• Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander have filed a Schedule 13G, indicating a joint filing for beneficial ownership.
• The filing pertains to the Common Stock of Reviva Pharmaceuticals Holdings, Inc.
• The aggregate amount beneficially owned by these entities is 1,072,690 shares.
• This represents 8.2% of the class of securities.
• The filing date for this amendment is June 30, 2026, with the report filed on July 31, 2026.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a neutral filing, primarily reporting on beneficial ownership changes rather than significant operational or financial performance.

Positives

• The reporting entities collectively hold a significant stake (8.2%) in Reviva Pharmaceuticals Holdings, Inc., which could indicate confidence in the company's future prospects.
• The joint filing agreement suggests a coordinated approach to ownership, potentially leading to more stable shareholding.

Negatives

• The filing does not provide any financial performance data or operational updates, limiting the ability to assess the company's health.
• The nature of the beneficial ownership (shared voting and dispositive power) implies a lack of sole control, which could lead to strategic uncertainties.

Risks

• The filing does not explicitly mention any risks associated with the investment or the company's operations.
• Potential for future changes in beneficial ownership by these large holders could impact stock price volatility.

Future Outlook

This filing is a Schedule 13G, which primarily reports on beneficial ownership and does not contain forward-looking statements or company guidance.

Management Comments

• The reporting entities certify that the securities were not acquired or held for the purpose of or with the effect of changing or influencing the control of the issuer.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors and hedge funds like Millennium Management when they acquire a significant stake in a public company. This filing indicates a substantial investment by these entities in Reviva Pharmaceuticals Holdings, Inc., a biotechnology or pharmaceutical company, though the specific sector focus isn't detailed in this document.

Comparison to Industry Standards

• The 8.2% ownership stake is a significant holding for a Schedule 13G filer, often indicating a passive investment strategy or a precursor to more active engagement.
• Hedge funds like Millennium Management are known for taking substantial positions in companies, and this filing aligns with typical investment patterns in the asset management industry.

Stakeholder Impact

• Shareholders: The significant stake held by Millennium entities may influence stock liquidity and potentially signal future strategic actions, impacting share price.
• Management: The increased institutional ownership might lead to closer scrutiny of company performance and strategy by these large investors.

Next Steps

• The reporting persons will continue to monitor their investment in Reviva Pharmaceuticals Holdings, Inc.
• Future filings may be required if there are significant changes in beneficial ownership.

Key Dates

Keywords

Schedule 13G, Beneficial Ownership, Reviva Pharmaceuticals Holdings, Millennium Management, Integrated Core Strategies, Investment Stake, Securities Exchange Act